GLP-1 Cost Comparison 2026: How to Save 40-60% on Weight Loss Medications

## GLP-1 Cost Comparison 2026: Complete Pricing Guide Cost is the single biggest barrier to GLP-1 therapy. A Diabetes Care study found that 40% of patients prescribed a GLP-1 medication never fill the prescription due to cost, and another 25% discontinue within 6 months for financial reasons. Understanding your options can save you thousands of dollars per year. This guide provides transparent, up-to-date pricing for every major GLP-1 medication available in 2026 -- brand, generic, and compounded. ## Complete Price Table: Brand vs. Compounded (2026) | Medication | Brand Name | Monthly (Brand, No Insurance) | Monthly (Brand, With Insurance) | Monthly (Compounded) | |-----------|-----------|-------------------------------|-------------------------------|---------------------| | **Semaglutide** | Ozempic (diabetes) | $900-1,100 | $25-300 | $150-250 | | **Semaglutide** | Wegovy (weight loss) | $1,300-1,500 | $0-500 | $150-250 | | **Tirzepatide** | Mounjaro (diabetes) | $1,000-1,100 | $25-300 | $250-400 | | **Tirzepatide** | Zepbound (weight loss) | $1,000-1,200 | $0-550 | $250-400 | | **Liraglutide** | Saxenda (weight loss) | $1,300-1,500 | $25-450 | $200-350 | | **Retatrutide** | N/A (not approved) | N/A | N/A | $300-500 | *Prices reflect typical U.S. market rates as of Q1 2026. Compounded pricing assumes standard maintenance doses.* ## Why Brand GLP-1 Medications Cost So Much The pricing of GLP-1 medications reflects several factors that have nothing to do with manufacturing cost: ### 1. R&D Amortization Novo Nordisk spent an estimated $2-4 billion developing semaglutide through clinical trials. Eli Lilly's tirzepatide program had similar costs. Brand pricing recovers these investments during the patent exclusivity period. ### 2. Marketing Expenditure GLP-1 manufacturers spend $500M+ annually on direct-to-consumer advertising. You are paying for those TV commercials. ### 3. PBM and Middleman Markups The pharmacy benefit manager (PBM) system adds 15-30% to the cost through rebates, spread pricing, and formulary placement fees. The list price you see is inflated to accommodate PBM negotiations. ### 4. Supply Constraints Semaglutide has been on the FDA shortage list since 2022. Limited supply enables premium pricing. ## How to Save: Five Strategies That Actually Work ### Strategy 1: Compounded Versions (Save 60-85%) Compounded semaglutide and tirzepatide offer the same active ingredient at a fraction of the cost. Key points: - Legal under FDA 503A/503B compounding exemptions - Available while branded versions remain on the drug shortage list - Require a prescription from a licensed provider - Best pharmacies provide batch-specific Certificates of Analysis **Monthly savings: $600-1,200 for semaglutide; $600-800 for tirzepatide** At [Prost](/products), compounded semaglutide starts at $199/month and tirzepatide at $299/month, including free shipping and third-party purity testing. ### Strategy 2: Manufacturer Savings Cards (Save $800-1,200/month) Both Novo Nordisk and Eli Lilly offer substantial savings programs: | Program | Eligibility | Savings | |---------|------------|---------| | **Ozempic Savings Card** | Commercially insured | As low as $25/month | | **Wegovy Savings Offer** | Commercially insured | As low as $0/month for 3 months | | **Mounjaro Savings Card** | Commercially insured | As low as $25/month | | **Zepbound Savings Card** | Commercially insured or cash-pay | As low as $25/month | **Limitations:** Government insurance (Medicare, Medicaid, Tricare) is excluded. Programs may have annual caps and can be discontinued without notice. ### Strategy 3: Insurance Optimization (Variable Savings) Steps to maximize insurance coverage: 1. **Get a diabetes diagnosis if applicable** -- GLP-1 coverage is significantly better for T2D than for weight loss 2. **Request prior authorization** -- Your prescriber can submit clinical justification 3. **Appeal denials** -- First-level appeals succeed 40-60% of the time 4. **Check formulary alternatives** -- Your plan may cover one GLP-1 but not another 5. **Consider employer advocacy** -- Some employers will add GLP-1 coverage upon request ### Strategy 4: Medicare Part D (New in 2025) The Inflation Reduction Act expanded Medicare Part D to cover anti-obesity medications starting in 2025. If you are on Medicare: - Anti-obesity medications (Wegovy, Zepbound) are now covered - Out-of-pocket costs capped at $2,000/year for all Part D drugs - Coverage applies to both diabetes and weight management indications ### Strategy 5: Dose Optimization (Save 20-40%) Many patients achieve excellent results at lower-than-maximum doses: - Semaglutide: 1.0-1.7mg may be sufficient (vs. maximum 2.4mg) - Tirzepatide: 7.5-10mg is the sweet spot for many (vs. maximum 15mg) - Lower doses = lower cost, fewer side effects, longer supply duration ## Annual Cost Comparison by Approach | Approach | Semaglutide Annual | Tirzepatide Annual | Retatrutide Annual | |----------|-------------------|-------------------|-------------------| | **Brand, no insurance** | $10,800-18,000 | $12,000-14,400 | N/A | | **Brand + savings card** | $300-3,600 | $300-3,600 | N/A | | **Brand + good insurance** | $600-3,600 | $600-3,600 | N/A | | **Compounded** | $1,800-3,000 | $3,000-4,800 | $3,600-6,000 | | **Compounded (Prost)** | $2,388/year | $3,588/year | $4,188/year | ## The Hidden Costs to Consider Beyond the medication itself, budget for: - **Prescriber consultations:** $50-200/visit (telehealth is cheaper) - **Lab work:** $50-150 per blood panel (2-4x/year recommended) - **Syringes/needles:** $5-15/month (for compounded vials) - **Shipping:** $0-25/month (many compounding pharmacies include shipping) - **Cold storage:** Minimal, but important -- semaglutide requires refrigeration ## The Bottom Line GLP-1 therapy does not have to cost $1,000+ per month. Between compounded versions, manufacturer savings cards, insurance optimization, and dose management, most patients can access effective GLP-1 therapy for $150-400/month. The key is knowing your options and being willing to explore alternatives to the default brand-at-list-price path. For a transparent, affordable option with pharmaceutical-grade quality assurance, visit [Prost's product page](/products) to see current pricing. --- ## References - IQVIA Institute. Prescription Drug Pricing in the United States: GLP-1 Agonist Market Analysis. 2025. - Gasoyan H, et al. Out-of-Pocket Costs and Adherence to GLP-1 Receptor Agonists. *Diabetes Care*, 2024. - Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Anti-Obesity Medications. 2025. - Grand View Research. Compounding Pharmacy Market Report: GLP-1 Medications. 2025.